Nielsen L S, Andreasen P A, Grøndahl-Hansen J, Huang J Y, Kristensen P, Danø K
Thromb Haemost. 1986 Apr 30;55(2):206-12.
Mouse monoclonal antibodies were derived against a plasminogen activator inhibitor with a mol. wt. of approximately 54,000 (54 K) from the human fibrosarcoma cell line HT-1080. Screening for hybrids producing antibodies directed against the inhibitor was performed with enzyme-linked immunosorbent assay and SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting. Four clones of hybridomas producing IgG1 antibodies were further characterized. The inhibitor was purified approximately 50-fold to homogeneity from conditioned cell culture fluid with a yield of approximately 85% by a one-step procedure using Sepharose-conjugated monoclonal antibody. In the 125I-fibrin plate assay one of the antibodies neutralized the effect of the inhibitor on urokinase-type plasminogen activator. Two of the antibodies bound complexes between urokinase-type plasminogen activator and inhibitor while the remaining two antibodies did not. The antibodies could be used for immunocytochemical localization of the inhibitor in HT-1080 cells. All four antibodies cross-reacted with a plasminogen activator inhibitor derived from cultured human umbilical cord endothelial cells.
小鼠单克隆抗体是针对一种来自人纤维肉瘤细胞系HT - 1080、分子量约为54,000(54K)的纤溶酶原激活物抑制剂产生的。通过酶联免疫吸附测定和SDS - 聚丙烯酰胺凝胶电泳(SDS - PAGE)随后进行免疫印迹,对产生针对该抑制剂抗体的杂交瘤进行筛选。对产生IgG1抗体的四个杂交瘤克隆进行了进一步表征。使用琼脂糖偶联的单克隆抗体通过一步法从条件细胞培养液中纯化该抑制剂,使其纯度提高约50倍达到均一性,产率约为85%。在125I - 纤维蛋白平板试验中,其中一种抗体中和了该抑制剂对尿激酶型纤溶酶原激活物的作用。两种抗体结合尿激酶型纤溶酶原激活物与抑制剂之间的复合物,而其余两种抗体则不结合。这些抗体可用于在HT - 1080细胞中对该抑制剂进行免疫细胞化学定位。所有四种抗体都与源自培养的人脐静脉内皮细胞的纤溶酶原激活物抑制剂发生交叉反应。